William M. Brandler

William M. Brandler

Auto-generated profile, based on publicly available information

William M. Brandler

Beyster Center for Genomics of Psychiatric Diseases, University of California San Diego, La Jolla, CA 92093, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2018 in Science
Verified
Journal Article
Closed access
PDF file
WBWilliam M. Brandler
William M. Brandler
DADanny Antaki
Danny Antaki
MGMadhusudan Gujral
Madhusudan Gujral
MKMorgan L. Kleiber
Morgan L. Kleiber
JWJoe Whitney
Joe Whitney
JSJonathan Sebat
Jonathan Sebat
Inherited variation contributes to autism: About one-quarter of genetic variants that are associated with autism spectrum disorder (ASD) are due to de novo mutations in protein-coding genes. Brandler et al. wanted to determine whether changes in noncoding regions of the genome are associated with autism. They applied whole-genome sequencing to ∼2600 families with at least one affected child. Children with ASD had inherited structural variants in noncoding regions from their father. Regulatory regions of some specific genes were disrupted among multiple families, supporting the idea that a component of autism risk involves inherited noncoding variation. Science , this issue p. 327

2 November 2026 in ChemRxiv
Verified
Preprint
Open access
WBWilliam Brandler
William Brandler
The LINE-1 retrotransposon is a virus-like genomic element that can activate in diseased cells. It has been implicated in cancer, autoimmunity, developmental disorders, infectious disease and neurodegeneration. LINE-1 can be inhibited by reverse transcriptase inhibitors, small molecules originally developed for HIV. The correlation between HIV and LINE-1 inhibition is ∼0.9 on a log scale, in spite of >450 Mya of evolutionary history since retroviruses diverged from retrotransposons. Suppression of HIV requires prevention of a completed 9.7 kb virus insertion into the genome in immune cells. However, every cell in the body already contains >100 copies of LINE-1 that can potentially activate. Even incomplete LINE-1 mediated insertions can cause damaging mutations and genome instability. Furthermore, partial HIV and LINE-1 products in the cytoplasm of cells can contribute to an inflammatory immune response. Preclinical studies have shown LINE-1 inhibitors slow the progression of otherwise unrelated diseases. LINE-1’s contribution to these diseases can potentially be quantified using single-nucleus whole-genome sequencing on diseased tissue, enabling prioritization of disease selection for therapeutic development. Furthermore, LINE-1’s ORF1p protein can be measured in the blood of individuals with certain cancers. LINE-1 inhibitors could therefore be extended to various diseases. Potentially used both as an anti-inflammatory and prophylactically to help preserve genome integrity. Reverse transcriptase inhibitors are available at low cost for HIV, and higher doses of some could be used to inhibit LINE-1. However, reverse transcriptase inhibitors do not prevent DNA cutting by LINE-1’s endonuclease. Novel inhibitors may therefore be required. This, combined with novel diagnostics opens up possibilities for inhibiting LINE-1 therapeutically in disease

29 October 2026 in ChemRxiv
Verified
Preprint
Open access
WBWilliam Brandler
William Brandler
The LINE-1 retrotransposon is a virus-like genomic element that can activate in diseased cells. It has been implicated in cancer, autoimmunity, developmental disorders, infectious disease and neurodegeneration. LINE-1 can be inhibited by reverse transcriptase inhibitors, small molecules originally developed for HIV. The correlation between HIV and LINE-1 inhibition is ∼0.9 on a log scale, in spite of >450 Mya of evolutionary history since retroviruses diverged from retrotransposons. Suppression of HIV requires prevention of a completed 9.7 kb virus insertion into the genome in immune cells. However, every cell in the body already contains >100 copies of LINE-1 that can potentially activate. Even incomplete LINE-1 mediated insertions can cause damaging mutations and genome instability. Furthermore, partial HIV and LINE-1 products in the cytoplasm of cells can contribute to an inflammatory immune response. Preclinical studies have shown LINE-1 inhibitors slow the progression of otherwise unrelated diseases. LINE-1’s contribution to these diseases can potentially be quantified using single-nucleus whole-genome sequencing on diseased tissue, enabling prioritization of disease selection for therapeutic development. Furthermore, LINE-1’s ORF1p protein can be measured in the blood of individuals with certain cancers. LINE-1 inhibitors could therefore be extended to various diseases. Potentially used both as an anti-inflammatory and prophylactically to help preserve genome integrity. Reverse transcriptase inhibitors are available at low cost for HIV, and higher doses of some could be used to inhibit LINE-1. However, reverse transcriptase inhibitors do not prevent DNA cutting by LINE-1’s endonuclease. Novel inhibitors may therefore be required. This, combined with novel diagnostics opens up possibilities for inhibiting LINE-1 therapeutically in disease

10 November 2026 in ChemRxiv
Verified
Preprint
Open access
PDF file
WBWilliam Brandler
William Brandler
The LINE-1 retrotransposon is a virus-like genomic element that can activate in diseased cells. It has been implicated in cancer, autoimmunity, developmental disorders, infectious disease and neurodegeneration. LINE-1 can be inhibited by reverse transcriptase inhibitors, small molecules originally developed for HIV. The correlation between HIV and LINE-1 inhibition is ∼0.9 on a log scale, in spite of >450 Mya of evolutionary history since retroviruses diverged from retrotransposons. Suppression of HIV requires prevention of a completed 9.7 kb virus insertion into the genome in immune cells. However, every cell in the body already contains >100 copies of LINE-1 that can potentially activate. Even incomplete LINE-1 mediated insertions can cause damaging mutations and genome instability. Furthermore, partial HIV and LINE-1 products in the cytoplasm of cells can contribute to an inflammatory immune response. Preclinical studies have shown LINE-1 inhibitors slow the progression of otherwise unrelated diseases. LINE-1’s contribution to these diseases can potentially be quantified using single-nucleus whole-genome sequencing on diseased tissue, enabling prioritization of disease selection for therapeutic development. Furthermore, LINE-1’s ORF1p protein can be measured in the blood of individuals with certain cancers. LINE-1 inhibitors could therefore be extended to various diseases. Potentially used both as an anti-inflammatory and prophylactically to help preserve genome integrity. Reverse transcriptase inhibitors are available at low cost for HIV, and higher doses of some could be used to inhibit LINE-1. However, reverse transcriptase inhibitors do not prevent DNA cutting by LINE-1’s endonuclease. Novel inhibitors may therefore be required. This, combined with novel diagnostics opens up possibilities for inhibiting LINE-1 therapeutically in disease

30 October 2026 in ChemRxiv
Verified
Preprint
Open access
WBWilliam Brandler
William Brandler
The LINE-1 retrotransposon is a virus-like genomic element that can activate in diseased cells. It has been implicated in cancer, autoimmunity, developmental disorders, infectious disease and neurodegeneration. LINE-1 can be inhibited by reverse transcriptase inhibitors, small molecules originally developed for HIV. The correlation between HIV and LINE-1 inhibition is ∼0.9 on a log scale, in spite of >450 Mya of evolutionary history since retroviruses diverged from retrotransposons. Suppression of HIV requires prevention of a completed 9.7 kb virus insertion into the genome in immune cells. However, every cell in the body already contains >100 copies of LINE-1 that can potentially activate. Even incomplete LINE-1 mediated insertions can cause damaging mutations and genome instability. Furthermore, partial HIV and LINE-1 products in the cytoplasm of cells can contribute to an inflammatory immune response. Preclinical studies have shown LINE-1 inhibitors slow the progression of otherwise unrelated diseases. LINE-1’s contribution to these diseases can potentially be quantified using single-nucleus whole-genome sequencing on diseased tissue, enabling prioritization of disease selection for therapeutic development. Furthermore, LINE-1’s ORF1p protein can be measured in the blood of individuals with certain cancers. LINE-1 inhibitors could therefore be extended to various diseases. Potentially used both as an anti-inflammatory and prophylactically to help preserve genome integrity. Reverse transcriptase inhibitors are available at low cost for HIV, and higher doses of some could be used to inhibit LINE-1. However, reverse transcriptase inhibitors do not prevent DNA cutting by LINE-1’s endonuclease. Novel inhibitors may therefore be required. This, combined with novel diagnostics opens up possibilities for inhibiting LINE-1 therapeutically in disease

28 October 2026 in ChemRxiv
Verified
Preprint
Open access
WBWilliam Brandler
William Brandler
The LINE-1 retrotransposon is a virus-like genomic element that can activate in diseased cells. It has been implicated in cancer, autoimmunity, developmental disorders, infectious disease and neurodegeneration. LINE-1 can be inhibited by reverse transcriptase inhibitors, small molecules originally developed for HIV. The correlation between HIV and LINE-1 inhibition is ∼0.9 on a log scale, in spite of >450 Mya of evolutionary history since retroviruses diverged from retrotransposons. Suppression of HIV requires prevention of a completed 9.7 kb virus insertion into the genome in immune cells. However, every cell in the body already contains >100 copies of LINE-1 that can potentially activate. Even incomplete LINE-1 mediated insertions can cause damaging mutations and genome instability. Furthermore, partial HIV and LINE-1 products in the cytoplasm of cells can contribute to an inflammatory immune response. Preclinical studies have shown LINE-1 inhibitors slow the progression of otherwise unrelated diseases. LINE-1’s contribution to these diseases can potentially be quantified using single-nucleus whole-genome sequencing on diseased tissue, enabling prioritization of disease selection for therapeutic development. Furthermore, LINE-1’s ORF1p protein can be measured in the blood of individuals with certain cancers. LINE-1 inhibitors could therefore be extended to various diseases. Potentially used both as an anti-inflammatory and prophylactically to help preserve genome integrity.